Investing.com — AC Immune Ltd (NASDAQ:ACIU) jumped 48% on Thursday after announcing positive developments for its Alzheimer’s treatment.
The small biopharmaceutical company has a single buy rating, according to data compiled by Investing.com. Shares retreated in afternoon trading, up 25%, to $9.
The company has begun the second highest dosing group in the Company’s Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimer’s disease. The decision to advance to the higher dosing group follows encouraging interim safety, tolerability and immunogenicity results from the initial dosing group. ACI-35.030, which is being developed in collaboration with Janssen Pharmaceuticals.